Compare Expedia Group Inc (EXPE) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Nuvalent Inc — how do they compare? Expedia Group Inc trades at $270.95 (market cap $32.06B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Expedia Group Inc is far larger — about 3.3× Nuvalent Inc's market cap, and Expedia Group Inc pays a 0.66% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| EXPE | NUVL | |
|---|---|---|
Market Cap | $32.06B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $301.31 | $123.96 |
52-Week Low | $178.06 | $72.16 |
Enterprise Value | $30.97B | $8.52B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $264.76, down 0.57% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with revenue growth to $14.73B in 2025 and consistent earnings beats, including Q1 2026 EPS of $1.96 versus $1.41 expected. Recent developments include a strategic partnership with Allegiant Travel and positive analyst coverage highlighting growth potential. Valuation metrics include a P/E of 23.6 and P/S of 2.29, indicating reasonable pricing relative to peers.
The outlook for EXPE is positive, driven by robust travel demand, strategic initiatives, and a consensus price target of $292.09 implying ~10% upside. Key risks include macroeconomic sensitivity affecting travel spending and competitive pressures. Institutional sentiment is bullish with 45% buy ratings, though investors should monitor execution on growth targets and industry cyclicality.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
